Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
DSGN · Why this verdict
Why Design Therapeutics (DSGN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Design Therapeutics is a pre-revenue, cash-burning biotech with a 4-quarter earnings beat streak and 84.5% upside to the analyst target, but weak quality (1.6/10), weak momentum (2.6/10) and a single-platform pipeline make it highly speculative.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business depends on one pipeline platform, GeneTAC platform technologies, flagged as a concentration risk, so a single clinical setback could impair the whole thesis. Bear case | Pipeline programs advance on the GeneTAC platform over the next 12 months without a major clinical setback. | ↓Deteriorating |
| CounterWith no revenue in recent quarters and one platform carrying all value, a failed trial in a binary biotech industry could erase most of the market value. | ||
Design Therapeutics is cash-burning (negative free cash flow) with no competitive moat and a quality score of 1.6, below the 4.0 floor. Quality breakdown | Cash burn stays funded and quality improves from 1.6 as the pipeline matures over ~12 months. | →Stable |
| CounterZero reported revenue in the latest quarters and a dependence on capital markets mean dilution risk is high, and a weak quality score gives no cushion if the pipeline slips. | ||
The company has beaten EPS estimates 4 quarters in a row (average surprise 14.1%), with the next report due in 12 days on 2026-11-05. Catalyst breakdown | EPS loss stays narrower than estimates at the 2026-11-05 report, extending the beat streak to 5 quarters. | →Stable |
| CounterBeats are on negative EPS, and the same company missed twice in 2025 (-3.0% and -10.7%); the streak says little about clinical value. | ||
The $18.89 analyst target is 84.5% above the $10.24 price, but coverage is light and the signal is dampened. Analyst target | Price moves toward the $18.89 target as pipeline news arrives, with the 84.5% upside gap narrowing. | →Stable |
| CounterWith light coverage, a few targets drive the number, and in biotech they often reset down fast after one disappointing data readout. | ||
Momentum is 2.6/10 with falling on-balance volume, a put/call ratio of 6.67 and implied volatility of 155%, though the 200-day average is still rising, so this may be a pullback in an uptrend. Momentum breakdown | Momentum recovers above 4.5 and the put/call ratio falls from 6.67 as the price stabilizes above the 200-day average. | ↑Improving |
| CounterHeavy put buying and 14% short interest signal informed bearish positioning, and the stock is 41% off its 52-week high with distribution volume. | ||
The business depends on one pipeline platform, GeneTAC platform technologies, flagged as a concentration risk, so a single clinical setback could impair the whole thesis.
↓DeterioratingBear case
- Expectation
- Pipeline programs advance on the GeneTAC platform over the next 12 months without a major clinical setback.
CounterWith no revenue in recent quarters and one platform carrying all value, a failed trial in a binary biotech industry could erase most of the market value.
Design Therapeutics is cash-burning (negative free cash flow) with no competitive moat and a quality score of 1.6, below the 4.0 floor.
→StableQuality breakdown
- Expectation
- Cash burn stays funded and quality improves from 1.6 as the pipeline matures over ~12 months.
CounterZero reported revenue in the latest quarters and a dependence on capital markets mean dilution risk is high, and a weak quality score gives no cushion if the pipeline slips.
The company has beaten EPS estimates 4 quarters in a row (average surprise 14.1%), with the next report due in 12 days on 2026-11-05.
→StableCatalyst breakdown
- Expectation
- EPS loss stays narrower than estimates at the 2026-11-05 report, extending the beat streak to 5 quarters.
CounterBeats are on negative EPS, and the same company missed twice in 2025 (-3.0% and -10.7%); the streak says little about clinical value.
The $18.89 analyst target is 84.5% above the $10.24 price, but coverage is light and the signal is dampened.
→StableAnalyst target
- Expectation
- Price moves toward the $18.89 target as pipeline news arrives, with the 84.5% upside gap narrowing.
CounterWith light coverage, a few targets drive the number, and in biotech they often reset down fast after one disappointing data readout.
Momentum is 2.6/10 with falling on-balance volume, a put/call ratio of 6.67 and implied volatility of 155%, though the 200-day average is still rising, so this may be a pullback in an uptrend.
↑ImprovingMomentum breakdown
- Expectation
- Momentum recovers above 4.5 and the put/call ratio falls from 6.67 as the price stabilizes above the 200-day average.
CounterHeavy put buying and 14% short interest signal informed bearish positioning, and the stock is 41% off its 52-week high with distribution volume.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 8.2 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 3.6 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+2.7%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 96%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.8 |
| growth rank | 5.0 |
Technical
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.8 |
| support resistance | 5.4 |
| 52w position | 2.8 |
Risk (lower is worse)
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.0 |
| days to cover | 0.4 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 4.4 |
| debt equity | 9.9 |
- ▸Elevated put/call: 5.00
- ▸High IV: 143%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.6 |
- ▸Perfect beat streak: 4Q
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:4.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:6d<=7d
Warning (0)
none
Reward-to-Risk
4.85
Upside
+70.5%
Downside
14.5%
Sizing output
AVOID
SetupRange Bound — RSI 46 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 6d<=7d outcome against Value at 9.0 and asymmetric R:R of 4.85.
The strongest dimensions are Value at 9.0, Catalyst at 7.4, and Insider at 7.3; the weakest are Quality at 1.6, Risk (lower is worse) at 2.5, and Technical at 4.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 4.85 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Genetac Pipeline Concentration
Trip ifShare price falls more than 40% from $10.24 on a clinical readout from the GeneTAC programs.
- P2Cash Burn Weak Quality
Trip ifQuality score falls below 1.0 from current 1.6.
- P3Earnings Beat Streak Catalyst
Trip ifEPS actual falls below estimate in 2 consecutive quarters, ending the 4-quarter beat streak.
- P4Analyst Target Upside Light Coverage
Trip ifAnalyst target falls below $12 from current $18.89.
- P5Weak Momentum High Volatility
Trip ifShort interest exceeds 20% from current 14%.